29 Feb HY Conference Call Transcript, page-4

  1. 3,846 Posts.
    lightbulb Created with Sketch. 2691
    Good morning Holders- 19 trading days left in March

    Si - from the transcript


    In contrast, use of our improved remestemcel product, Ryoncil, has shown a 100-day survival of 67% when used under expanded access in 51 adults and children with steroid refractive GVHD who otherwise fail to respond to at least one additional agent beyond steroids including ruxolitinib.

    Presentation
    Slide 20 -
    3. Expanded Access Protocol (EAP 275), n= 241. Day 100 survival 66%.


    Question - Does this indicate 51 adults have been treated under an EAP? Significant if so - or is it a combined number of adults/kids. Given that we n=241 for kids on a separate slide.

    What's my point? The upcoming, funded trial , will only have to recruit and treat circa 70 adults patients and current standard of care is less than 30 % survival. It's like the trial has already been performed- control arm in the forthcoming trial won't survive. Isn't science fun....

    51 adults already documented at 67% survival - these must have been salvage patients to qualify for the EAP.

    Apologies if I have missed the company stating Adult EAP numbers earlier- if someone knows, please confirm.

    Thanks

    Reg

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.70
Change
-0.145(7.88%)
Mkt cap ! $2.159B
Open High Low Value Volume
$1.81 $1.83 $1.69 $8.843M 5.089M

Buyers (Bids)

No. Vol. Price($)
14 24522 $1.69
 

Sellers (Offers)

Price($) Vol. No.
$1.70 15403 9
View Market Depth
Last trade - 13.05pm 02/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.